Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Ranganath, Praveen ^a   Einhorn, Lawrence ^a   Albany, Costantine ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIZAPRIDE; APREPITANT; CHLORPROMAZINE; CISPLATIN; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; METOCLOPRAMIDE; OLANZAPINE; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; PATIENT PREFERENCE; PRACTICE GUIDELINE; REVIEW; VISUAL ANALOG SCALE; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; NAUSEA; PATHOPHYSIOLOGY; VOMITING;

CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; NAUSEA; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 84941712150     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/943618     Document Type: Review

References (45)

1. L. H. Einhorn, "Curingmetastatic testicular cancer," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 7, pp. 4592-4595, 2002.
2. T. S. Herman, L. H. Einhorn, S. E. Jones et al., "Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy," The New England Journal of Medicine, vol. 300, no. 23, pp. 1295-1297, 1979.
3. P. J. Hornby, "Central neurocircuitry associated with emesis," The American Journal of Medicine, vol. 111, no. 8, supplement 1, pp. 106S-112S, 2001.
4. P. J. Hesketh, S. Van Belle, M. Aapro et al., "Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists," European Journal of Cancer, vol. 39, no. 8, pp. 1074-1080, 2003.
5. P. Diemunsch and L. Grelot, "Potential of substance P antagonists as antiemetics," Drugs, vol. 60, no. 3, pp. 533-546, 2000.
6. G. J. Sanger, "Neurokinin NK 1 and NK 3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain," British Journal of Pharmacology, vol. 141, no. 8, pp. 1303-1312, 2004.
7. G. Wampler, "The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapyinduced emesis," Drugs, vol. 25, supplement 1, pp. 35-51, 1983.
8. A. Stoudemire, P. Cotanch, and J. Laszlo, "Recent advances in the pharmacologic and behavioral management of chemotherapy-induced emesis," Archives of Internal Medicine, vol. 144, no. 5, pp. 1029-1033, 1984.
9. E. D. Bruera, E. Roca, L. Cedaro, R. Chacón, and R. Estévez, "Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant tometoclopramide," Cancer Treatment Reports, vol. 67, no. 4, pp. 381-383, 1983.
10. S. E. Sallan, N. E. Zinberg, and E. Frei III, "Antiemetic effect of delta-9 tetrahydrocannabinol in patients receiving cancer chemotherapy,"The New England Journal of Medicine, vol. 293, no. 16, pp. 795-797, 1975.
11. L. H. Einhorn, C. Nagy, B. Furnas, and S. D. Williams, "Nabilone: an effective antiemetic in patients receiving cancer chemotherapy," Journal of Clinical Pharmacology, vol. 21, no. 8-9, pp. 64S-69S, 1981.
12. E. Meiri, H. Jhangiani, J. J. Vredenburgh et al., "Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting," Current Medical Research and Opinion, vol. 23, no. 3, pp. 533-543, 2007.
13. L. X. Cubeddu, I. S.Hoffmann,N. T. Fuenmayor, andA. L. Finn, "Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting," The New England Journal of Medicine, vol. 322, no. 12, pp. 810-816, 1990.
14. L. H. Einhorn, C. Nagy, K. Werner, and A. L. Finn, "Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy," Journal of Clinical Oncology, vol. 8, no. 4, pp. 731-735, 1990.
15. G. W. Sledge Jr., L. Einhorn, C. Nagy, and K. House, "Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy," Cancer, vol. 70, no. 10, pp. 2524-2528, 1992.
16. K. Jordan, A. Hinke, A. Grothey et al., "A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis," Supportive Care in Cancer, vol. 15, no. 9, pp. 1023-1033, 2007.
17. K. Bremer, "A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy," European Journal of Cancer Part A: General Topics, vol. 28, no. 6-7, pp. 1018-1022, 1992.
18. A. Noble, K. Bremer, L. Goedhals, D. Cupissol, and S. G. Dilly, "A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group," European Journal of Cancer, vol. 30, no. 8, pp. 1083-1088, 1994.
19. O. Geling and H.-G. Eichler, "Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic reevaluation of clinical evidence and drug cost implications," Journal of Clinical Oncology, vol. 23, no. 6, pp. 1289-1294, 2005.
20. P. J. Hesketh,W. H. Harvey,W. G. Harker et al., "A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis," Journal of Clinical Oncology, vol. 12, no. 3, pp. 596-600, 1994.
21. S. M. Fox, L. H. Einhorn, E. Cox, N. Powell, and A. Abdy, "Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy," Journal of Clinical Oncology, vol. 11, no. 12, pp. 2391-2395, 1993.
22. A.A.Fauser,G. Pizzocaro, J. Schueller,D. Khayat, andP.Wilkinson, "A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatinrelated nausea and vomiting," Supportive Care in Cancer, vol. 8, no. 1, pp. 49-54, 2000.
23. L. H. Einhorn, M. J. Brames, R. Dreicer, C. R. Nichols, M. T. Cullen Jr., and J. Bubalo, "Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer," Supportive Care in Cancer, vol. 15, no. 11, pp. 1293-1300, 2007.
24. C. Albany, M. J. Brames, C. Fausel, C. S. Johnson, J. Picus, and L. H. Einhorn, "Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group study," Journal of Clinical Oncology, vol. 30, no. 32, pp. 3998-4003, 2012.
25. S.Hamada, S. Hinotsu, K. Kawai et al., "Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germcell tumor receiving 5-day cisplatin-based combination chemotherapy," Supportive Care in Cancer, vol. 22, no. 8, pp. 2161-2166, 2014.
26. L. H. Einhorn, S. M. Grunberg, B. Rapoport, C. Rittenberg, and P. Feyer, "Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement," Supportive Care in Cancer, vol. 19, supplement 1, pp. S1-S4, 2011.
27. J. Vardy, K. S. Chiew, J. Galica, G. R. Pond, and I. F. Tannock, "Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy," British Journal of Cancer, vol. 94, no. 7, pp. 1011-1015, 2006.
28. A. M. Cook, A. S. K. Dzik-Jurasz, A. R. Padhani, A. Norman, and R. A. Huddart, "The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours," British Journal of Cancer, vol. 85, no. 11, pp. 1624-1626, 2001.
29. R. Stoltz, J.-C. Cyong, A. Shah, and S. Parisi, "Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects," The Journal of Clinical Pharmacology, vol. 44, no. 5, pp. 520-531, 2004.
30. K. Aogi, H. Sakai, H. Yoshizawa et al., "A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy," Supportive Care in Cancer, vol. 20, no. 7, pp. 1507-1514, 2012.
31. F. Longo, G. Mansueto, V. Lapadula et al., "Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy," International Journal of Clinical Practice, vol. 66, no. 8, pp. 753-757, 2012.
32. R. M. Navari, R. R. Reinhardt, R. J. Gralla et al., "Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group," The New England Journal of Medicine, vol. 340, no. 3, pp. 190-195, 1999.
33. P. J. Hesketh, S. M. Grunberg, R. J. Gralla et al., "The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group," Journal of Clinical Oncology, vol. 21, no. 22, pp. 4112-4119, 2003.
34. S. Poli-Bigelli, J. Rodrigues-Pereira, A. D. Carides et al., "Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapyinduced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America," Cancer, vol. 97, no. 12, pp. 3090-3098, 2003.
35. H. J. Schmoll, M. S. Aapro, S. Poli-Bigelli et al., "Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment," Annals of Oncology, vol. 17, no. 6, pp. 1000-1006, 2006.
36. J. B.McCrea, A. K. Majumdar,M. R.Goldberg et al., "Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone," Clinical Pharmacology andTherapeutics, vol. 74, no. 1, pp. 17-24, 2003.
37. M. Di Maio, E. Bria, G. L. Banna et al., "Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors," Anti-Cancer Drugs, vol. 24, no. 2, pp. 99-111, 2013.
38. J. J. Hale, S. G. Mills, M. MacCoss et al., "Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs," Journal ofMedicinal Chemistry, vol. 43, no. 6, pp. 1234-1241, 2000.
39. H. Saito, H. Yoshizawa, K. Yoshimori et al., "Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapyinduced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebocontrolled phase 3 trial," Annals of Oncology, vol. 24, no. 4, pp. 1067-1073, 2013.
40. P. J. Hesketh, G. Rossi, G. Rizzi et al., "Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study," Annals of Oncology, vol. 25, no. 7, pp. 1340-1346, 2014.
41. L. Tan, J. Liu, X. Liu et al., "Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting," Journal of Experimental and Clinical Cancer Research, vol. 28, no. 1, article 131, 2009.
42. R. M. Navari, S. E. Gray, and A. C. Kerr, "Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial," Journal of Supportive Oncology, vol. 9, no. 5, pp. 188-195, 2011.
43. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Antiemesis. Version 1, National Comprehensive Cancer Network, 2014, http://www.nccn.org/professionals/physician gls/f guidelines.asp.
44. E. Basch, P. J. Hesketh, M. G. Kris, A. A. Prestrud, S. Temin, and G. H. Lyman, "Antiemetics: american society of clinical oncology clinical practice guideline update," Journal of Oncology Practice, vol. 7, no. 6, pp. 395-398, 2011.
45. R. J.Gralla, F. Roila,M. Tonato, and J.Herrstedt,MASCC/ESMO Antiemetic Guideline 2013, 2013, http://www.mascc.org/assets/ Guidelines-Tools/mascc antiemetic english 2014.pdf.